Therapeutic Group

Indication Dosage

Filgrastim is a medication primarily indicated for the treatment of neutropenia, a condition characterized by a low count of white blood cells (neutrophils). It is commonly used to boost the production of these crucial white blood cells in patients undergoing chemotherapy, which can suppress the immune system and lead to an increased risk of infections. By stimulating the bone marrow to produce more neutrophils, Filgrastim helps to strengthen the body's defenses against infections, ultimately improving the overall well-being of individuals receiving cancer treatment or undergoing certain medical procedures.

Reduction In Duration Of Neutropenia And Incidence Of Febrile Neutropenia In Cytotoxic Chemotherapy For Malignancy: 

By Sc Inj Or Iv Infusion: 

• Adult & Children 1 Mth-18 Yr: 5 Mcg/kg Daily Started Not Less Than 24 Hr After Cytotoxic Chemotherapy, Continued Until Neutrophil Count In Normal Range, Usually For Up To 14 Days (up To 38 Days In Acute Myeloid Leukaemia) 

Reduction In Duration Of Neutropenia (and Associated Sequelae) In Myeloablative Therapy Followed By Bone-marrow Transplantation: 

By IV Infusion Or Sc Infusion: 

• Adult & Children 1 Month-18 Yrs: 10 Mcg/kg Daily, Started Not Less Than 24 Hr Following Cytotoxic Chemotherapy (and Within 24 Hr Of Bone-marrow Infusion), Then Adjusted According To Absolute Neutrophil Count. 

Bmt Cancer: 

By Sc Or Iv Infusion: 

• Adults: Initial: 10 Mcg/kg/day 

Peripheral Blood Progenitor Cell Collection: 

By Sc Inj: 

• Adults: Initially 10 Mcg/kg/day Four Day Before & For 6-7 days with Leukapheresis On Day 5th, Day 6th & Day 7th. 

Mobilisation Of Peripheral Blood Progenitor Cells For Autologous Infusion, Used Alone: 

By Sc Inj Or Sc Infusion: 

• Adult & Children 1 Month-18 Yrs: 10 Mcg/kg Daily For 5-7 Days 

Mobilization Of Peripheral Blood Progenitor Cells For Autologous Infusion Following Adjunctive Myelosuppressive Chemotherapy (to Improve Yield): 

By Sc Inj: 

• Adult & Children 1 Month-18 Yrs: 5 Mcg/kg Daily, Started The Day After Completion Of Chemotherapy And Continued Until Neutrophil Count In Normal Range; For Timing Of Leucopheresis Consult Product Literature. 

Mobilisation Of Peripheral Blood Progenitor Cells In Normal Donors For Allogeneic Infusion: 

By Sc Inj: 

• Adult & Children Above 16 Yr: 10 Mcg/kg Daily For 4-5 Days; For Timing Of Leucopheresis Consult Product Literature. 

Severe Congenital Neutropenia And History Of Severe Or Recurrent Infections: 

By IV Infusion: 

• Adult: Initially 12 Mcg/kg Daily, Adjusted According To Response, Can Be Given In Single Or Divided Doses, Consult Product Literature. 

Severe Cyclic Neutropenia, Or Idiopathic Neutropenia And History Of Severe Or Recurrent Infections: 

By IV Infusion: 

• Adult: Initially 5 Mcg/kg Daily, Adjusted According To Response, Can Be Given In Single Or Divided Doses, Consult Product Literature And Local Protocol 

Severe Chronic Neutropenia: 

By Sc Inj: 

• Adult & Children 1 Month-18 Yrs: Initially 12 Mcg/kg Daily In Single Or Divided Doses (initially 5 Mcg/kg Daily In Idiopathic Or Cyclic Neutropenia), Adjusted According To Response (consult Product Literature). 

Persistent Neutropenia In Hiv Infection: 

By Sc Inj: 

• Adult & Children 1 Mth 18 Yr: Initially 1 Mcg/kg Daily, Increased As Necessary Until Absolute Neutrophil Count In Normal Range (usual Max 4 Mcg/kg Daily), Then Adjusted To Maintain Absolute Neutrophil Count In Normal Range (consult Product Literature).

Content

Pregnancy

Risk Cannot Be Ruled Out, Should Not Be Used During Pregnancy Unless The Potential Benefit Outweighs The Risk.

Stability

Contra Indications

Precautions

Lactation

Side Effects